GlassScriptPhysician profile
Russ L Levitan
NPI 1992783302
$4,715.98
in general payments reported to CMS, 2019-2025
27 companies · $416 in 2025
The $416 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $239 · 2021: $586 · 2022: $320 · 2023: $839 · 2024: $1,612 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.71 |
| Education | $357.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,664.14 | 2022-2025 | Accurian, Intellis Adaptivestim, Synchromedii |
| Tersera Therapeutics LLC | $719.28 | 2019-2025 | Prialt |
| Abbvie INC. | $503.42 | 2021-2025 | |
| Medtronic USA, INC. | $404.31 | 2019 | |
| Abbott Laboratories | $356.31 | 2019-2021 | |
| Allergan, INC. | $194.88 | 2019-2022 | |
| Boston Scientific Corporation | $177.48 | 2019-2024 | Superion Indirect Decompression System |
| Vertex Pharmaceuticals Incorporated | $100.23 | 2024-2025 | |
| Pfizer INC. | $95.75 | 2021-2025 | |
| Spr Therapeutics, INC | $80.14 | 2023 | Sprint Pns System |
| Grt US Holding, INC. | $73.21 | 2022 | |
| Nevro Corp. | $34.36 | 2023 | Senza |
| Avanos Medical | $32.48 | 2024 | Genvisc 850 Sodium Hyaluronate |
| Relievant Medsystems, INC. | $28.09 | 2021 | |
| Nalu Medical, INC. | $27.90 | 2024 | Nalu Neurostimulation System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.28 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $22.86 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $22.80 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.61 | 2020 | |
| Supernus Pharmaceuticals, INC. | $20.05 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.89 | 2023 | Ajovy |
| Scilex Pharmaceuticals INC. | $19.32 | 2021 | |
| Baudax Bio INC. | $16.41 | 2022 | |
| Depuy Synthes Sales INC. | $15.51 | 2019 | |
| Assertio Therapeutics, INC. | $14.77 | 2019 | |
| Lundbeck LLC | $14.06 | 2020 | |
| Ibsa Pharma INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russ Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.